help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feuillan, P. P.
Right arrow Articles by Cutler, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feuillan, P. P.
Right arrow Articles by Cutler, G. B., Jr

Journal of Clinical Endocrinology & Metabolism, Vol 73, 1370-1373, Copyright © 1991 by Endocrine Society

ARTICLES

Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome

PP Feuillan, J Jones, KE Oerter, PK Manasco and GB Cutler Jr
Developmental Endocrinology Branch, National Institute of Chile Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.

Two girls with precocious puberty (chronological age, 1 and 4 yr; bone age, 3 and 6 yr, respectively) were initially given the diagnosis of idiopathic, central precocious puberty and treated with the LHRH agonist deslorelin (D-Trp6-Pro9-NEt-LHRH) for 5 yr. Unlike other girls with central precocious puberty, both had persistently elevated rates of growth and bone maturation, and both menstruated during therapy. One girl had episodic ovarian enlargement and markedly elevated serum estradiol levels due to recurrent unilateral ovarian cysts. Although the bone and skin manifestations of McCune-Albright syndrome were absent, we hypothesize that the underlying defect of McCune-Albright syndrome was expressed in the ovaries, but not in the skin or bones, of these two girls. One of these girls appeared to benefit from the aromatase inhibitor testolactone, which is effective in suppressing precocious puberty in girls with the McCune-Albright syndrome.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
S. J. Marx and W. F. Simonds
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Endocr. Rev., August 1, 2005; 26(5): 615 - 661.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. Y. Adashi and J. D. Hennebold
Single-Gene Mutations Resulting in Reproductive Dysfunction in Women
N. Engl. J. Med., March 4, 1999; 340(9): 709 - 718.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. A. Cummings, S. R. Salisbury, M. L. Givner, and R. S. Rittmaster
Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact?
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 784 - 787.
[Abstract] [Full Text]

Home page
 NEJMHome page
J. A. Majzoub and R. E. Scully
Case 7-1993- A Six-Year-Old Boy with Multiple Bone Lesions, Repeated Fractures, and Sexual Precocity
N. Engl. J. Med., February 18, 1993; 328(7): 496 - 502.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society